Diplomat Receives Full URAC Specialty Pharmacy Reaccreditation
FLINT, Mich. – December 17, 2015 – The nation’s largest independent specialty pharmacy has been fully reaccredited by URAC without requiring any corrective action.
Diplomat Pharmacy, Inc. (NYSE: DPLO) announced today that it has been awarded full Specialty Pharmacy reaccreditation by URAC, a Washington, D.C.–based health care accrediting organization that establishes quality standards for the health care industry. Diplomat has been fully accredited for Specialty Pharmacy since 2012.
URAC is an independent, nonprofit health care accrediting organization dedicated to promoting health care quality through accreditation, education, and measurement. URAC offers a wide range of quality benchmarking programs that reflect the latest changes in health care and provide a symbol of excellence for organizations to showcase their validated commitment to quality and accountability. URAC’s evidence-based measures and standards are developed through inclusive engagement with a broad range of stakeholders committed to improving the quality of health care.
“We are extremely proud to have received reaccreditation as a specialty pharmacy provider for URAC,” said Gary Kadlec, Diplomat’s president. “This demonstrates our continued education and commitment to achieve high clinical service standards of quality and accountability.”
URAC’s accreditation is nationally recognized by state and federal regulators to ensure the highest level of quality is delivered to consumers. URAC accreditation and its programs and standards appear in state legislation, state regulation, and federal regulation. URAC has deemed status in state and federal certification programs and is authorized by Health and Human Services as an accreditor for Qualified Health Plans in the Health Insurance Marketplace.
“URAC’s mission to promote continuous improvements in the quality and efficiency of health care management aligns with our mission to support patients in the quality of their care,” said Jennifer Hagerman, Diplomat’s associate vice president of education and quality.
To learn more about Diplomat, visit www.diplomat.is.
This press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements give current expectations or forecasts of future events or our future financial or operating performance. The forward-looking statements contained in this press release are based on management’s good-faith belief and reasonable judgment based on current information. These statements are qualified by important risks and uncertainties, many of which are beyond our control, that could cause our actual results to differ materially from those forecasted or indicated by such forward-looking statements. For a discussion of such risks and uncertainties, you should review Diplomat’s filings with the Securities and Exchange Commission, including “Risk Factors” in Diplomat’s Annual Report on Form 10-K for the year ended December 31, 2014 and in subsequent reports filed with or furnished to the Securities and Exchange Commission. Except as may be required by any applicable laws, Diplomat assumes no obligation to publicly update such forward-looking statements, which are made as of the date hereof or the earlier date specified herein, whether as a result of new information, future developments or otherwise.
Diplomat (NYSE: DPLO) serves patients and physicians in all 50 states. Headquartered in Flint, Michigan, the company focuses on medication management programs for people with complex chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, HIV, specialized infusion therapy and many other serious or long-term conditions. Diplomat opened its doors in 1975 as a neighborhood pharmacy with one essential tenet: “Take good care of patients, and the rest falls into place.” Today, that tradition continues—always focused on improving patient care and clinical adherence. For more information visit www.diplomat.is. Follow us on Twitter and LinkedIn and like us on Facebook.
Kali Lucas, Public Relations Coordinator
810.768.9580 | email@example.com
Jennifer Hagerman, PharmD
Associate Vice President, Education and Quality
810.768.9330 | firstname.lastname@example.org
@PharmacDailyRT @PharmacDaily: @DiplomatRx to distribute Puma Biotechnology’s new cancer drug $DPLO https://t.co/gl0v6WURVV5 days ago
@DiplomatRxNerlynx (neratinib) tablets for HER2+ Breast Cancer in the Extended Adjuvant Setting https://t.co/vi3ACWhbfe5 days ago
@AJPB_JournalRT @AJPB_Journal: Be sure to check out our Insights page featuring videos of Cheryl Allen from @DiplomatRx discussing #RA https://t.co/qxZc…2 weeks ago
@DiplomatRxWe're with @340BCoalition this week in Washington D.C.! Come say hello.3 weeks ago
@SpecialtyPTimesRT @SpecialtyPTimes: Rheumatoid Arthritis Treatment Guidelines https://t.co/sEhe74UozC #rheumatoidarthritis @DiplomatRx3 weeks ago